注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Lipocine Inc是一家临床阶段的生物制药公司。该公司应用其口服给药技术开发用于神经内分泌和代谢紊乱的药物产品。该公司拥有一系列针对男性和女性的神经和精神中枢神经系统(CNS)疾病、肝病和激素补充剂未满足的需求的候选产品。该公司的候选产品TLANDO是一种由十一酸睾酮(TU)组成的口服睾酮替代疗法(TRT)。该公司的其他候选药物包括LPCN 1148、LPCN 1144、LPCN 1111(TLANDO XR)、LPCN 1107、LPCN 1154和LPCN 2101。该公司的LPCN 1144是由TU组成的生物相同睾酮的口服前药,用于治疗非肝硬化非酒精性的脂肪性肝炎(NASH),已完成II期测试。该公司的TLANDO XR是一种口服TRT产品,由十三酸睾酮(TT)组成,已完成II期试验。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Jill M. Jene | 49 | 2022 | Independent Director |
Mahesh V. Patel | 65 | 1997 | Co-Founder, Interim Principal Financial Officer, Director, President & CEO |
Rex P. Hjelm | - | - | Member of Scientific Advisory Board |
William N. Charman | 63 | - | Member of Scientific Advisory Board |
Richard Dana Ono | 70 | 2014 | Independent Director |
Alan F. Hofmann | - | - | Member of Scientific Advisory Board |
George Zografi | - | - | Member of Scientific Advisory Board |
Leslie Z. Benet | 85 | - | Member of Scientific Advisory Board |
Tsuneji Nagai | - | - | Member of Scientific Advisory Board |
John W. Higuchi | 55 | 2003 | Director |
Bradley D. Anderson | - | - | Member of Scientific Advisory Board |
Ronald T. Borchardt | - | - | Member of Scientific Advisory Board |
Norman Ho | - | - | Member of Scientific Advisory Board |
Jeffrey Arvin Fink | 65 | 2014 | Independent Director |
Spyridon Papapetropoulos | 51 | 2022 | Lead Independent Director & Chairman of the Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核